Pliant Therapeutics shares climbed 6.0% in pre-open trading after regulators granted Fast Track status to PLN-101095, the company’s oral, dual selective inhibitor of the αvβ8 and αvβ1 integrins, for use alongside the immunotherapy pembrolizumab in patients whose solid tumors have stopped responding to immune checkpoint inhibitors. The company announced the designation this morning in a formal press release.
The Fast Track designation is intended to accelerate the development and review of therapies that target serious conditions with significant unmet medical needs. For Pliant, the decision represents an important regulatory endorsement of its oncology direction following the company’s strategic pivot away from its earlier fibrosis program.
PLN-101095 is currently enrolled in the Phase 1a/1b FORTIFY trial. That study is recruiting patients with non-small cell lung cancer, tumors with high tumor mutational burden, and clear cell renal cell carcinoma. Pliant has said it expects clinical data readouts from the program in 2027.
Financially, the company reported approximately $159.6 million in cash, cash equivalents, and short-term investments in its most recent quarterly filing. Management indicated that those resources are expected to fund operations into the second half of 2028, which reduces the immediacy of dilution risk and supports continuity for the clinical program.
The broader market provided no offsetting support for PLRX’s pre-market move. The NASDAQ was under notable pressure and the S&P 500 was trading in negative territory at the same time, indicating that the stock’s advance was driven by company-specific news rather than sector or market momentum.
There were no analyst upgrades or competitor sympathy rallies identified as contributing factors on this date. The stock remains well below its 52-week high of $1.95, reflecting that investors still attribute meaningful clinical-stage risk to Pliant’s pipeline despite the regulatory recognition.
In short, the FDA’s Fast Track designation for PLN-101095 acted as the primary catalyst for today’s movement in PLRX shares. While Fast Track status does not imply eventual approval, it does enable more frequent engagement with the FDA and may allow for rolling review, procedural benefits that investors in clinical-stage biotechnology companies commonly regard as de-risking milestones.
Summary
FDA Fast Track designation for PLN-101095 in combination with pembrolizumab drove a 6.0% pre-open rise in Pliant Therapeutics shares. The program is in Phase 1a/1b and targets multiple tumor types with anticipated data in 2027. The company reported roughly $159.6 million in cash and equivalents, supporting operations into H2 2028. The move was company-specific amid weak broader market performance.